|
|
|
|
|
|
 | Retroperitoneal pararenal isolated neurofibroma: report of a case and review of literature
| | C Corbellini, A Vingiani, F Maffini, A Chiappa, E Bertani and B Andreoni |  | Anterior prostatic tumours are difficult to diagnose without MRI
| | G Petralia, S Alessi, A Alconchel, P Summers, G Musi, V Matei, O De Cobelli, G Renne and M Bellomi |  | Inflammatory breast cancer: is it really a separate entity?
| | AS Bastawisy, RM Gaafar, SS Eisa, GM Amira, and MH Helal |  | Phase 0 clinical trials: towards a more complete ethics critique
| | TP Hill |  | 30th German Cancer Congress, 22nd–25th February 2012, Berlin
| | L Budiner |  | Erratum: Cancer stem cells in melanoma
| | C Regenbrecht, Y Welte, R Hugel, U Trefzer, FO Losch, J Adjaye and P Walden |  | A rare case of a phyllodes tumour of the breast converting to a fibrosarcoma with successful treatment
| | NK Pant, A Singh, D Kumar and H Pandey |  | Circulating microRNAs: next-generation biomarkers for early lung cancer detection
| | F Bianchi, F Nicassio, G Veronesi and PP di Fiore |
|
|  | | |
|
|
 | Recent developments in neoadjuvant therapy
Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany |  | Highlights and goals of IMPAKT 2012
Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium |  | PI3K and the heterogeneity of small tumour breast cancer
Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium |  | Molecularly characterising triple negative breast cancer
Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium |  | Endocrine therapy and endocrine resistant breast cancer
Prof Mitch Dowsett – The Institute for Cancer Research, London, UK |  | Neoadjuvant therapy and PCR through chemotherapy prior to surgery
Dr Michail Ignatiadis – Jules Bordet Institute, Brussels, Belgium |  | Minimising recurrence by using most effective treatment
Prof Fabrice Andre – Institut Gustave Roussy, Paris, France |  | Overcoming drug resistance and targeting critical pathways
Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New York, USA |  | Heterogeneity of tumours and the challenges of biomarker development
Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy |  | Targeting the PI3K/mTOR pathway
Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA |
|
|
| | | |
|
| |
